This presentation discusses DME management, focusing on transitioning to high-dose aflibercept following suboptimal responses ...
This comprehensive presentation examines complex retinal disease management using sequential anti-VEGF therapies, supported ...
Commercial shipments for VIZZ will begin in October, with availability in retail pharmacies expected by mid-Q4 2025.
Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital ...
Mario Romano, MD, PhD: One of the topics that I presented on at EURETINA was the temperature control during the vitrectomy.
Treatment-Resistant AMD and Diabetic Macular EdemaWith High-Dose Aflibercept Summary. This presentation examines the management of treatment-resistant retinal conditions using hig ...
David Lally, MD, presented at the 2025 Retina Society meeting, discussing the ARCHER study (NCT04656561) of ANX007 for the treatment of age-related macular degeneration (AMD) and geographic atrophy ...
Opus Genetics today announced the positive 3-month pediatric data from its Phase 1/2 open-label, ascending-dose study of the ...
This technology bridges research and clinical practice, enhancing patient monitoring and prognostication by providing ...
Following the assembly of the prototype, the OCT researchers were able to present the first high-resolution images of the eye ...
The ACTOR study finds OCT angiography cannot predict exudative recurrence in neovascular AMD but offers valuable vascular ...
The AVONELLE-X study confirms sustained visual gains and treatment durability of faricimab for wet AMD over four years. 80% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results